K. Muni Raja Lakshmi
Department of Pharmaceutics, S.V.U.College of Pharmaceutical Sciences, S.V.University, Tirupati, A.P, India-517501
Abstract
RA occurs as erosive synovitis, symmetric, lead to joint and cartilage damage, significant disability, and reduction in quality of life. Tenoxicam (4-hydroxy-2-methyl-N-(pyridine-2-yl)-2Hthieno- 1,2-thiazine-3-carboxamide-1,1-dioxide) (1) is a NonSteroidal Anti-Inflammatory Drug (NSAID), with analgesic and antipyretic properties.. It is indicated for treatment of rheumatoid arthritis and to control acute pain. It is a BCS class II drug. To improve its solubility it was prepared as solid dispersions by solvent evaporation method using PEG 25000, PVP K-30, and Sodium Starch Glycolate as polymers. Then they were evaluated and the promising formulation was prepared as transdermal patch. The the patch was evaluated and the promising formulation which had highest amount of in-vitro drug release was evaluated for pharmacodynamics activity. At the end of the treatment the inflammation on both hind paws of treated rats were reduced compared to untreated rats. Transdermal patches of tenoxicam made with solid dispersions of tenoxicam were used to treat the rheumatoid arthritis in rats
Key Words: Rheumatoid arthritis, Tenoxicam, Solid dispersions, Transdermal patch.